New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
09:14 EDTDRTXDurata Therapeutics price target raised to $22 from $19 at JMP Securities
JMP Securities increased its price target on Durata after the company priced its Dalvance drug at the higher end of the range expected by the firm. The firm reiterates an Outperform rating on Durata.
News For DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
16:18 EDTDRTXActavis, Durata announce FTC grants early termination of HSR Act
Actavis (ACT) and Durata Therapeutics (DRTX) announced that the FTC has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Actavis' pending acquisition of Durata. The early termination of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in Q4.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use